COVID-19患者における死亡率の生化学的および血液学的予測因子

Supaporn Wiwattanakul¹, Rutchaporn Taweerutchana², Kitsarawut Khuancharee³

¹Department of Pathology, HRH Princess Maha Chakri Sirindhorn Medical Center, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok 26120, Thailand.

Medical sciences (Basel, Switzerland)

|December 24, 2025

要旨

Background:

Coronavirus disease (COVID-19), caused by SARS-CoV-2 infection, presents a broad spectrum of clinical manifestations, ranging from asymptomatic cases to severe and fatal outcomes. Studies have shown that laboratory parameters fluctuate in patients with COVID-19, and these parameters serve as valuable biomarkers for monitoring disease progression. This study examines the relationship between changes in biochemical and hematological markers and patient survival among early COVID-19 cases.

Materials And Methods:

In this retrospective cohort study, data from adult (≥18 years) hospitalized COVID-19 patients with positive PCR results at HRH Princess Maha Chakri Sirindhorn Medical Center, Srinakharinwirot University, Nakhon Nayok, Thailand, between March and December 2021, were analyzed. Univariate and multivariate logistic regression analyses were conducted on mortality-related laboratory parameters. All measures are reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs).

Results:

The cohort included 397 patients with pneumonia (median age: 52.2 years (IQR: 40.5-64.6); 61.96% female). Among them, 42 patients (10.58%) succumbed during hospitalization, with a median hospital stay of 12.92 days (IQR: 10.03-15.94). Independent mortality predictors were identified as follows: age (aOR = 1.11; 95% CI: 1.04-1.19; p = 0.002), potassium (aOR = 6.27; 95% CI: 1.31-29.93; p = 0.021), creatinine (aOR = 1.62; 95% CI: 1.05-2.50; p = 0.028), hemoglobin A1c (aOR = 1.96; 95% CI: 1.30-2.97; p = 0.001), and red cell distribution width (aOR = 1.45; 95% CI: 1.05-2.02; p = 0.026), respectively. Furthermore, patients with lower platelet counts had a notably higher risk of mortality (aOR = 0.98; 95% CI: 0.97-0.99; p = 0.001).

Conclusions:

Our findings suggest that age, potassium, creatinine, hemoglobin A1c, red cell distribution width, and platelet count are significant predictors of mortality risk in patients with COVID-19. Clinicians should consider these biochemical and hematological markers critically before initiating treatment for COVID-19 patients.

キーワード:

COVID-19 生化学的マーカー臨床バイオマーカー血液学的マーカー死亡率予測因子

関連する概念動画

01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

749

01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...

516